|
Stories from the dialysis comunity across the globe.
|
|
Symplicity trial discussed by Drs. Gersh and Lerman. |
 |
 |
|
To help put things in perspective, and underlining the power of the placebo effect.
|
|
|
Negative SYMPLICITY HTN-3 trial results published in NEJM |
|
|
|
NEJM: Conclusions. This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control
|
|
Evolocumab lowers LDL cholesterol by more than 50% (NEJM) |
|
|
|
NEJM: Among the 901 patients included in the primary analysis, the overall least-squares mean (+/-SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0 +/-2.1% (P<0.001).
|
|
|
SYMPLICITY HTN - 3: Renal artery denervation fails for resistant hypertension |
|
|
|
ACC: Despite meeting primary safety endpoints, SYMPLICITY HTN-3 – the pivotal U.S. trial examining renal denervation for treatment-resistant hypertension – has fallen short of its secondary efficacy goals, and failed to reach its primary efficacy endpoint as announced earlier this year by the study's sponsor. The new data was released March 29 as part of ACC.14 in Washington, DC, and simultaneously published in the New England Journal of Medicine (NEJM).
|
|
New class of anticholesterol drugs lowers LDL by 50% |
|
|
|
Huffingtonpost: Three studies of Amgen Inc.'s version of these drugs, called evolocumab (ev-oh-LOKE-you-mab), found it lowered LDL or "bad" cholesterol by 55 to 66 percent compared to a fake drug, and by nearly that much when compared to Merck's Zetia, another cholesterol medication.
|
|
|
|
|
<< Start < Prev 411 412 413 414 415 416 417 418 419 420 Next > End >>
|
|
Page 413 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
